natgillin/translations-raw huggingface dataset:
The apparatus according to claim 8 or 9, wherein the demultiplexer (1313a; 1313b) is configured to perform demultiplexing on the interleaved bits according to a code rate of the error-correction coding method in the second information. 
Uređaj prema patentnom zahtjevu 8 ili 9, naznačen time što je demultipleksor (1313a; 1313b) konfiguriran za provođenje demultipleksiranja na bitove za preplitanje prema kodnom omjeru postupkom kodiranja za ispravak pogrešaka u drugoj informaciji.
The apparatus according to claim 8 to 10, wherein a least significant bit LSB or a most significant bit MSB of the bits mapped to the symbol is determined by demultiplexing the interleaved bits according to the error-correction coding method in the second information, 
Uređaj prema patentnom zahtjevu 8 do 10, naznačen time što je mapiranje bitova u simbol najmanje značajnog bita LSB ili više značajnog bita MSB utvrđeno pomoću demultipleksiranja bitova za preplitanje prema postupku kodiranja za ispravak pogrešaka u drugoj informaciji.
a bit deinterleaver (2476a; 2476b) for deinterleaving the multiplexed bits; and an error correction decoder (253) for error-correction-decoding the deinterleaved bits. 
rasplitač bitova (2476a; 2476b) za rasplitanje multipleksiranih bitova; i dekoder za ispravak pogrešaka (253) za dekodiranje za ispravak pogrešaka bitova za rasplitanje.
The apparatus according to claim 12, wherein the symbol de-mapper is configured to perform demapping on the symbol by a symbol de-mapping method being one of QPSK, 16-QAM, 64-QAM and/or 256-QAM. 
Uređaj prema patentnom zahtjevu 12, naznačen time što je demaper simbola konfiguriran za provođenje demapiranja na simbol pomoću postupka demapiranja simbola koje je jedno od QPSK, 16-QAM, 64-QAM i / ili 256-QAM.
The apparatus according to claim 12 or 13, wherein the multiplexer (2475a; 2475b) is configured to perform multiplexing on the bits according to the error-correction coding method in the second information. 
Uređaj prema patentnom zahtjevu 12 ili 13, naznačen time što je multipleksor (2475a; 2475b) konfiguriran za provođenje multipleksiranja na bitovima prema postupku kodiranja za ispravak pogrešaka u drugoj informaciji.
is selected from the group consisting of hydrogen and methyl; 
je odabran iz skupine koju sačinjavaju vodik i metil;
is selected from the group consisting of hydrogen and halo; 
je odabran iz skupine koju sačinjavaju vodik i halo;
is selected from the group consisting of C1-C4-alkyl, C3-C6-carbocyclyl, and 5-6-membered heterocyclyl, wherein: 
je odabran iz skupine koju sačinjavaju C1-C4-alkil, C3-C6-karbociklil, i 5-6-člani heterociklil, pri čemu:
the alkylsulfonyl optionally is substituted with one or two substituents independently selected from the group consisting of carboxy, hydroxy, halo, amino, nitro, oxo, aminosulfonyl, alkyloxycarbonyl, alkylcarbonyloxy, alkyloxy, carbocyclyl, heterocyclyl, cyano, and aminocarbonyl; and 
alkilsulfonil je opcijski supstituiran s jednim ili dva supstituenta neovisno odabranima iz skupine koju sačinjavaju karboksi, hidroksi, halo, amino, nitro, okso, aminosulfonil, alkiloksikarbonil, alkilkarboniloksi, alkiloksi, karbociklil, heterociklil, cijano i aminokarbonil; i
is selected from the group consisting of hydroxy and methoxy; 
je odabran iz skupine koju sačinjavaju hidroksi i metoksi;
RA is hydrogen; and RB is hydrogen. 
RA je vodik; i RB je vodik.
The compound or salt of claim 1, wherein the compound is selected from the group consisting of: 
Spoj ili sol prema zahtjevu 1, naznačen time, da je spoj odabran iz skupine koja sadrži:
Use of a therapeutically effective amount of a salt according to claim 1 for manufacturing a medicament for treating a disease which responds to an inhibition of protein kinase activity. 
Uporaba terapeutski učinkovite količine soli prema zahtjevu 1, naznačena time, da je za proizvodnju lijeka za liječenje bolesti koja odgovara inhibiciji djelovanja proteinske kinaze.
The antibody or antigen binding fragment thereof according to claims 1 or 2 wherein the antibody is selected from the group consisting of; intact, chimaeric, humanised, bispecific, heteroconjugate. 
Protutijelo, ili njegov antigenski vežući fragment, u skladu s patentnim zahtjevima 1 ili 2, naznačeno time što protutijelo se bira iz skupine koju čine: cjelovito, kimerno, humanizirano, bispecifično, te heterokonjugirano.
The antibody of claim 4 wherein the intact antibody is murine, rat, rabbit, primate or human. 
Protutijelo u skladu s patentnim zahtjevom 4, naznačeno time što cjelovito protutijelo je mišje, štakorsko, kunićje, primatsko ili ljudsko.
and the human light chain comprises the following residues: 
[image] a ljudski laki lanac sadrži sljedeće ostatke:
A antibody according to claim 13 wherein the constant region is of an IgG isotype e.g. IgG1 or IgG4. 
Protutijelo u skladu s patentnim zahtjevom 13, naznačeno time što konstantno područje je IgG izotipa, primjerice IgG1 ili IgG4.
A antibody according to claim 14 wherein the constant region is IgG1. 
Protutijelo u skladu s patentnim zahtjevom 14, naznačeno time što konstantno područje je IgG1.
A antibody according to claim 15 wherein the constant region is mutated to render the antibody non-lytic. 
Protutijelo u skladu s patentnim zahtjevom 15, naznačeno time što konstantno područje je mutirano, kako bi se protutijelo učinilo nelitičkim.
The pharmaceutical composition of claim 21 for use in the treatment of psoriasis. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 21, naznačen time što je namijenjen upotrebi u liječenju psorijaze.
Use of an antibody or antigen binding fragment of any one of claims 1 to 20 in the manufacture of a medicament for the treatment of rheumatoid arthritis, osteoarthritis, psoriasis, asthma or COPD. 
Upotreba protutijela, ili antigenski vežućeg fragmenta, u skladu s bilo kojim od patentnih zahtjeva 1 do 20, naznačena time što je navedeno protutijelo, ili antigenski vežući fragment, namijenjeno proizvodnji medikamenta za liječenje reumatoidnog artritisa, osteoartritisa, psorijaze, astme ili COPD.
A vector (e.g. plasmid) encoding the heavy chain and/or light chain of the antibody or antigen binding fragment of any one of claims 1 to 20, for example said vector comprises a polynucleotide of any one of claims 28 to 31 
Vektor (primjerice plazmid) koji kodira teški lanac i/ili laki lanac protutijela, ili antigenski vežućeg fragmenta, u skladu s bilo kojim od patentnih zahtjeva 1 do 20, naznačen time što, primjerice, navedeni vektor sadrži polinukleotid u skladu s bilo kojim od patentnih zahtjeva 28 do 31.
The host cell of claim 36 wherein said cell is CHO or NS0. 
Stanica-domaćin u skladu s patentnim zahtjevom 36, naznačena time što navedena stanica je CHO ili NS0.
A process as claimed claim 6 wherein the transition metal catalyst is on a carbon support. 
Postupak prema zahtjevu 6 naznačen time da je katalizator od prijelaznog metala na ugljikovoj podlozi.
A process as claimed in claim 9 wherein the hydrogenation of a compound of formula (II) is conducted at a temperature in the range 20 to 40°C. 
Postupak prema zahtjevu 9 naznačen time da se hidrogeniranje spoja formule (II) provodi na temperaturi u rasponu od 20 do 40°C.
A process as claimed in claim 11 wherein the hydrogenation of a compound of formula (II) is conducted at a pressure of 2 to 4 bar. 
Postupak prema zahtjevu 11 naznačen time da se hidrogeniranje spoja formule (II) provodi pri tlaku od 2 do 4 bar.
A method according to claim 1 or 2 characterised in that (+)- O, O' -di- p -toluoyl-(S,S)-tartaric acid is used. 
Postupak prema zahtjevu 1 ili 2, naznačen time što se upotrebljava (+)-O,O’-di-p-toluoil-(S,S)-vinska kiselina.
A method according to claim 1 or 2 characterised in that (-)- O, O' -di- p -toluoyl-(R,R)-tartaric acid is used. 
Postupak prema zahtjevu 1 ili 2, naznačen time, što se upotrebljava (-)-O,O’-di-p-toluoil- (R,R)-vinska kiselina.
A method according to claim 7 characterised in that the achiral acid is selected from the group consisting of organic acids. 
Postupak prema zahtjevu 7, naznačen time što je ahiralna kiselina izabrana iz grupe koja se sastoji od organskih kiselina.
A method according to any one of claims 1-14 characterised in that the separated salt is re-slurried or recrystallised one or more times in a solvent system comprising 1-propanol or ethanol by heating to a temperature in the range from 30 °C to the reflux temperature for the solvent. 
Postupak prema bilo kojem od zahtjeva 1-14, naznačen time što se izdvojena sol ponovo suspendira ili rekristalizira jednom ili više puta u sustavu otapala koji sadrži 1-propanol ili etanol zagrijanjem do temperature u opsegu od do temperature refluksa otapala.
A method according to claim 18 wherein the S-4-[4-(dimethylamino)-1-(4'-fluorophenyl)-1-hydroxybutyl]-3-(hydroxymethyl)-benzonitrile is reacted with a reactive acid derivative such as an acid chloride or acid anhydride in the presence of a base. 
Postupak prema zahtjevu 18, naznačen time, što S-4-[4-(dimetilamino)-1-(4'-fluorofenil)-1-hidroksibutil]-3-(hidroksimetil)-benzonitril reagira sa derivatom reaktivne kiseline kao što je kiseli klorid ili kiseli anhidrid, u prisustvu baze.
The immunogenic composition of any preceding claim wherein the 19F saccharide is conjugated to the carrier protein or to the linker using CDAP chemistry for use in the treatment or prevention of diseases caused by Streptococcus pneumoniae infection by serotype 19A strains. 
Imunogeni pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, gdje je saharid iz serotipa 19F konjugiran s proteinom-nosačem ili sa spojnicom uz pomoć CDAP kemije, naznačen time što je namijenjen upotrebi u liječenju ili sprječavanju bolesti uzrokovanih infekcijom sojevima serotipa 19A bakterije Streptococcus pneumoniae.
The immunogenic composition of any preceding claim wherein the average size (e.g. Mw) of the 19F saccharide is above 100 kDa for use in the treatment or prevention of diseases caused by Streptococcus pneumoniae infection by serotype 19A strains. 
Imunogeni pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, gdje je prosječna veličina (primjerice u Mw) saharida iz serotipa 19F iznad 100 kDa, naznačen time što je namijenjen upotrebi u liječenju ili sprječavanju bolesti uzrokovanih infekcijom sojevima serotipa 19A bakterije Streptococcus pneumoniae.
A method according to claim 5, characterized in that said chitosan, water soluble amino-polysaccharide chitosan derivative and/or physiologically acceptable salt thereof is applied to the nail surface freely. 
Postupak u skladu s patentnim zahtjevom 5, naznačen time što navedeni kitozan, u vodi topivi derivat aminopolisaharida kitozana i/ili njegova fiziološki prihvatljiva sol se bez ograničenja primijenjuje na površinu nokta.
A method according to claim 1, characterized in that said chitosan, water soluble amino-polysaccharide chitosan derivative and/or physiologically acceptable salt thereof is administered by means of a topical formulation. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što navedeni kitozan, u vodi topivi derivat aminopolisaharida kitozana i/ili njegovu fiziološki prihvatljivu sol se primijenjuje uz pomoć topikalne formulacije.
the amino portion of such substituents optionally is substituted with a substituent independently selected from the group consisting of carbocyclylalkyl, heterocyclylalkyl, alkylcarbonyloxy, aminocarbonylalkyl, alkyl, alkenyl, alkynyl, alkylcarbonyl, alkenylcarbonyl, alkynylcarbaaxyl, alkyloxycarbonyl, alkyloxyalkyloxycarbonyl, alkylcarbonyloxyalkyl, and alkylsulfonyl, wherein: 
amino dio od takvih supstituenata je opcijski supstituiran sa supstituentom neovisno odabranim iz skupine koju sačinjavaju karbociklilalkil, heterociklilalkil, alkilkarboniloksi, aminokarbonilalkil, alkil, alkenil, alkinil, alkilkarbonil, alkenilkarbonil, alkinilkarbonil, alkiloksikarbonil, alkiloksialkiloksikarbonil, alkilkarboniloksialkil i alkilsulfonil, pri čemu:
A transgenic mouse comprising a transgenic nucleotide sequence encoding Qpct operably linked to a promoter, integrated into the genome of the mouse, wherein the mouse demonstrates a phenotype that can be reversed or ameliorated with a Qpct inhibitor. 
Transgenični miš koji hipereksprimira glutaminil-ciklazu, naznačen time što sadrži transgenični nukleotidni slijed koji kodira glutaminil-ciklazu, operabilno vezan na promotor, integriran u genom miša, gdje miš pokazuje fenotip kojeg se može poništiti ili ublažiti inhibitorom glutaminil-ciklaze.
A method for screening for therapeutic agents that inhibit or promote Qpct activity comprising 
Postupak pretraživanja na terapijska sredstva koja inhibiraju ili potiču aktivnost glutaminil-ciklaze, naznačen time što se sastoji u
transmitting a signal including the modulated signal frame via at least one frequency band, the method characterised in that the signal includes first information and second information, the second information has information for the code rate of the error-correction coding method and the first information has information for indicating a fast fourier transformation, FFT, size used for an OFDM symbol for the second information. 
moduliranje signalnog okvira (S160) pomoću metode multipleksiranja s ortogonalnom podjelom frekvencija OFDM i prijenos signala uključujući modulirani signalni okvir putem najmanje jednog frekvencijskog opsega, karakteriziran pri čemu signal uključuje prvu informaciju i drugu informaciju, druga informacija ima informaciju postupka kodiranja za ispravak pogrešaka i prva informacija ima informaciju za indiciranjem brze Fourierove transformacije, FFT, veličine korištene za OFDM simbole druge informacije.
The compound as claimed in claim 3, wherein the organic solvents are selected from the group consisting of alcohols, esters, alkanes, and alkyl halides. 
Spoj prema patentnom zahtjevu 3, naznačen time, da se organska otapala odabiru iz skupine koja se sastoji od alkohola, estera, alkana i alkil-halogenida.
The cyclohexenone compound as claimed in claim 24, wherein the organic solvents are selected from the group consisting of alcohols, esters, alkanes, and alkyl halides. 
Cikloheksenonski spoj prema patentnom zahtjevu 24, naznačen time, da se organska otapala odabiru iz skupine koja se sastoji od alkohola, estera, alkana i alkil-halogenida.
The cyclohexenone compound as claimed in claim 8, wherein the breast cancer cells are from MCF-7 or MDA-MB-231 cell line. 
Cikloheksenonski spoj prema patentnom zahtjevu 8, naznačen time, da su stanice karcinoma dojke iz MCF-7 ili MDA-MB-231 stanične linije.
The cyclohexenone compound as claimed in claim 22, wherein the prostate cancer cells are from LNCaP or DU145 cell line. 
Cikloheksenonski spoj prema patentnom zahtjevu 22, naznačen time, da su stanice karcinoma prostate iz LNCaP ili DU145 stanične linije.
A pharmaceutical composition for inhibiting growth of tumor cells comprising an active dose of the compound as claimed in claim 1 and a pharmaceutically-acceptable carrier, wherein the tumor cells are selected from the group consisting of breast cancer, hepatic cancer, and prostate cancer. 
Farmaceutski sastav za inhibiranje rasta tumorskih stanica, naznačen time, da sadrži aktivnu dozu spoja prema patentnom zahtjevu 1, te farmaceutski prihvatljivi nosilac, u čemu se tumorske stanice odabiru iz skupine koja se sastoji od karcinoma dojke, karcinoma jetre i karcinoma prostate.
is one of the following: 
je jedno od sljedećeg:
coupling in an aprotic solvent a compound of formula (II): 
sprega spoja formule (II) u aprotičnom otapalu:
The method of claim 1, wherein in step c) the compound of formula (II) is treated with 3.0 equivalent of Lewis acid and is added to a solution of 1.0 equivalent of ester (Int5). 
Metoda iz zahtjeva 1, pri čemu se u koraku c) spoj formule (II) tretira ekvivalentom 3,0 Lewisove kiseline te se dodaje u otopinu ekvivalenta 1,0 estera (Int5).
The method of claim 2, wherein the Lewis acid is trimethylaluminium. 
Metoda iz zahtjeva 2, pri čemu je Lewisova kiselina trimetilaluminij.
The method of claim 1, wherein in step c) a solution of 1.0 equivalent of acid chloride (Int5) is added to a solution of 0.8 equivalent of the compound of formula (II). 
Metoda iz zahtjeva 1, pri čemu se u koraku c) u otopinu ekvivalenta 0,8 spoja formule (II) dodaje otopina ekvivalenta 1,0 kiselinskog klorida (Int5).
The method of claim 5, wherein the base is triethylamine. 
Metoda iz zahtjeva 5, pri čemu je lužina trietilamin.
The method of claim 1, wherein in step c) 1.0 equivalent of the compound of formula (II) is coupled with 1.1 equivalent of benzoic acid (Int5). 
Metoda iz zahtjeva 1, pri čemu se u koraku c) ekvivalent 1,0 spoja formule (II) spreže s ekvivalentom 1,1 benzojeve kiseline (Int5).
The method of claim 8, wherein the activating agent is Mukaiyama's Reagent (2-Chloro-1-methylpyridinium iodide). 
Metoda iz zahtjeva 8, pri čemu je aktivator Mukaiyamin reagens (2-kloro-1-metilpiridinijev jodid).
The method according to claim 1, wherein in step a) the reaction mixture is diluted with water and the precipitated product is isolated by filtration. 
Metoda prema zahtjevu 1, pri čemu se u koraku a) reakcijska mješavina razrjeđuje vodom, a precipitat se izolira filtriranjem.
The method according to one of the preceding claims, wherein in step b) the compound of formula (II) obtained by reduction of the corresponding nitro compound is performed by hydrogenation. 
Metoda prema jednom od prethodnih zahtjeva, pri čemu se u koraku b) dobivanje spoja formule (II) redukcijom odgovarajućeg dušičnog spoja odvija hidrogenacijom.
The method of claim 12, wherein the catalyst is Raney Nickel. 
Metoda iz zahtjeva 12, pri čemu je katalizator Raney-nikal.
The method of claim 16, wherein the reaction is performed in a polar protic solvent. 
Metoda iz zahtjeva 16, pri čemu se reakcija odvija u polarnom protičnom otapalu.
The process according to claim 11, wherein in step b) the reaction mixture is diluted with water and the precipitated product is isolated by filtration. 
Postupak prema zahtjevu 11, pri čemu se u koraku b) reakcijska mješavina razrjeđuje vodom, a precipitat se izolira filtriranjem.
The method of claim 16, wherein the base is potassium carbonate. 
Metoda iz zahtjeva 16, pri čemu je lužina kalijev karbonat.
The method of claim 19, wherein the reaction is performed in aprotic solvent. 
Metoda iz zahtjeva 19, pri čemu se reakcija odvija u aprotičnom otapalu.
The method according to claim 19, wherein the reaction mixture is diluted with water and the precipitated product is isolated by filtration. 
Metoda prema zahtjevu 19, pri čemu se u reakcijska mješavina razrjeđuje vodom, a precipitat se izolira filtriranjem.
A compound according to claim 4, or a pharmaceutically acceptable salt thereof, wherein R1 is SO2CH3. 
Spoj u skladu s patentnim zahtjevom 4 ili njegova farmaceutski prihvatljiva sol, naznačen time, da R1 je SO2CH3.
A compound according to claim 11, or a pharmaceutically acceptable salt thereof, wherein R3 is methyl and the stereocentre produced has the (R)-configuration. 
Spoj u skladu s patentnim zahtjevom 11 ili njegova farmaceutski prihvatljiva sol, naznačen time, da R3 je metil, a nastali stereocentar ima (R)-konfiguraciju.
a second active ingredient which is a muscarinic antagonist which is Aclidinium bromide, Glycopyrrolate, Oxitropium bromide, Pirenzepine, telenzepine or Tiotropium bromide; and, a pharmaceutically acceptable adjuvant, diluent or carrier. 
drugi aktivni sastojak koji je muskarinski antagonist kao aklidinij bromid, glikopirolat, oksitropij bromid, pirenzepin, telenzepin ili tiotropij bromid; te farmaceutski prihvatljivu pomoćnu tvar, razrjeđivač ili nosač.
Use according to claim 6 or 7, wherein the respiratory disease is chronic obstructive pulmonary disease or asthma. 
Uporaba prema zahtjevu 6 ili 7, naznačena time, da je respiratorna bolest kronična opstruktivna plućna bolest ili astma.
Xaa at position 80 is Asn or Ala; and Xaa at position 230 is Lys or is absent. 
Xaa na položaju 80 je Asn ili Ala; i Xaa na položaju 230 je Lys ili je odsutan.
The heterologous fusion protein of claim 2 wherein the linker comprises the sequence of SEQ ID NO:8. 
Heterologni fuzijski protein u skladu s patentnim zahtjevom 2, naznačen time što spojnica sadrži slijed SEQ ID NO:8.
Xaa at position 80 is Asn; and Xaa at position 230 is absent; and 
Xaa na položaju 80 je Asn; i Xaa na položaju 230 je odsutan; i
The heterologous fusion protein of any one of claims 1 to 11 for use in the treatment of non-insulin dependent diabetes mellitus. 
Heterologni fuzijski protein u skladu s bilo kojim od patentnih zahtjeva 1 do 11, naznačen time što je namijenjen upotrebi u liječenju dijabetes melitusa neovisnog o inzulinu.
The heterologous fusion protein of any one of claims 1 to 11 for use in the treatment of obesity or inducement of weight loss in an overweight subject. 
Heterologni fuzijski protein u skladu s bilo kojim od patentnih zahtjeva 1 do 11, naznačen time što je namijenjen upotrebi u liječenju pretilosti ili poticanju gubitka na težini kod pretilog subjekta.
A formulation comprising any one of the heterologous fusion proteins according to claims 1 to 11. 
Formulacija, naznačena time što sadrži bilo koji od heterolognih fuzijskih proteina u skladu s patentnim zahtjevima 1 do 11.
A heterologous fusion protein of any one of claims 1 to 8 for use in the treatment of obesity or inducement of weight loss in an overweight subject. 
Heterologni fuzijski protein u skladu s bilo kojim od patentnih zahtjeva 1 do 11, naznačen time što je namijenjen upotrebi u liječenju pretilosti ili poticanju gubitka na težini kod pretilog subjekta.
A composition which comprises the following myelin basic protein peptides: 
Smjesa koja sadrži sljedeće peptide mijelinskog bazičnog proteina:
A composition according to claim 1, consisting essentially of the following myelin basic protein peptides: 
Smjesa prema zahtjevu 1 koja se u biti sastoji od sljedećih peptida mijelinskog bazičnog proteina:
A composition according to claim 1 or 2 for use in treating or preventing a disease. 
Smjesa prema zahtjevu 1 ili 2 za uporabu u liječenju ili prevenciji bolesti.
A composition according to claim 1 or 2 for use in treating or preventing multiple sclerosis. 
Smjesa prema zahtjevu 1 ili 2 za uporabu u liječenju ili prevenciji multiple skleroze.
A composition according to claim 1 or 2 for use in treating or preventing optic neuritis associated with multiple sclerosis 
Smjesa prema zahtjevu 1 ili 2 za uporabu u liječenju ili prevenciji optičkog neuritisa koji je povezan s multiplom sklerozom.
A composition for use according to claim 3 or 4 for administration following a dose-escalation protocol. 
Smjesa za uporabu prema zahtjevu 3 ili 4 za primjenu nakon protokola postupnog povećavanja doze.
A composition for use according to claim 3 or 4 for administration to an HLA-DQ6 or HLA-DR2 positive subject. 
Smjesa za uporabu prema zahtjevu 3 ili 4 za primjenu subjektu koji je pozitivan na HLA-DQ6 ili HLA-DR2.
A kit which comprises the following myelin basic protein peptides: 
Kit koji sadrži sljedeće peptide mijelinskog bazičnog proteina:
MBP 131-145; and MBP 140-154 for simultaneous, separate or sequential administration. 
MBP 131-145; i MBP 140-154 za istodobnu, odvojenu ili uzastopnu primjenu.
A pharmaceutical composition including (i) an active ingredient selected from: a compound of claim 1, a pharmaceutically acceptable salt of claim 2 or 3, and a prodrug of claim 4; and (ii) a pharmaceutically acceptable diluent, excipient or carrier. 
Farmaceutska smjesa koja sadrži (i) djelatnu tvar koja se izabire između: spoja prema zahtjevu 1, farmaceutski prihvatljive soli prema zahtjevu 2, i prolijeka prema zahtjevu 3; i (ii) farmaceutski prihvatljivo punilo, pomoćnu tvar ili nosač.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide and as component (B) fludioxonil. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-il)amid, te kao komponentu (B) fluopiram.